vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与Rocket Lab Corp（RKLB）财务数据对比。点击上方公司名可切换其他公司
Rocket Lab Corp的季度营收约是DYNAVAX TECHNOLOGIES CORP的1.9倍（$179.7M vs $94.9M），DYNAVAX TECHNOLOGIES CORP净利率更高（28.4% vs -29.5%，领先57.8%），Rocket Lab Corp同比增速更快（35.7% vs 17.7%），DYNAVAX TECHNOLOGIES CORP自由现金流更多（$32.6M vs $-114.2M），过去两年Rocket Lab Corp的营收复合增速更高（39.2% vs 30.6%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
Rocket Lab是公开上市的航空航天制造商及发射服务提供商，旗下Electron轨道火箭主打小型卫星发射，截至2026年1月已成功完成超75次任务，是全球现役发射次数最多的小型运载火箭。公司还开发了Electron的亚轨道改型HASTE用作高超音速技术测试平台，下一代可复用中型运载火箭Neutron目前也在研发中。
DVAX vs RKLB — 直观对比
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $179.7M |
| 净利润 | $26.9M | $-52.9M |
| 毛利率 | — | 38.0% |
| 营业利润率 | 22.4% | -28.4% |
| 净利率 | 28.4% | -29.5% |
| 营收同比 | 17.7% | 35.7% |
| 净利润同比 | 53.0% | -1.1% |
| 每股收益（稀释后） | $0.21 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | — | $179.7M | ||
| Q3 25 | $94.9M | $155.1M | ||
| Q2 25 | $95.4M | $144.5M | ||
| Q1 25 | $68.2M | $122.6M | ||
| Q4 24 | $72.0M | $132.4M | ||
| Q3 24 | $80.6M | $104.8M | ||
| Q2 24 | $73.8M | $106.3M | ||
| Q1 24 | $50.8M | $92.8M |
| Q4 25 | — | $-52.9M | ||
| Q3 25 | $26.9M | $-18.3M | ||
| Q2 25 | $18.7M | $-66.4M | ||
| Q1 25 | $-96.1M | $-60.6M | ||
| Q4 24 | $7.0M | $-52.3M | ||
| Q3 24 | $17.6M | $-51.9M | ||
| Q2 24 | $11.4M | $-41.6M | ||
| Q1 24 | $-8.7M | $-44.3M |
| Q4 25 | — | 38.0% | ||
| Q3 25 | — | 37.0% | ||
| Q2 25 | — | 32.1% | ||
| Q1 25 | — | 28.8% | ||
| Q4 24 | — | 27.8% | ||
| Q3 24 | — | 26.7% | ||
| Q2 24 | — | 25.6% | ||
| Q1 24 | — | 26.1% |
| Q4 25 | — | -28.4% | ||
| Q3 25 | 22.4% | -38.0% | ||
| Q2 25 | 15.1% | -41.3% | ||
| Q1 25 | -34.7% | -48.3% | ||
| Q4 24 | -2.3% | -38.9% | ||
| Q3 24 | 12.5% | -49.5% | ||
| Q2 24 | 7.0% | -40.7% | ||
| Q1 24 | -35.0% | -46.4% |
| Q4 25 | — | -29.5% | ||
| Q3 25 | 28.4% | -11.8% | ||
| Q2 25 | 19.6% | -46.0% | ||
| Q1 25 | -141.0% | -49.5% | ||
| Q4 24 | 9.8% | -39.5% | ||
| Q3 24 | 21.8% | -49.6% | ||
| Q2 24 | 15.4% | -39.2% | ||
| Q1 24 | -17.2% | -47.7% |
| Q4 25 | — | $-0.09 | ||
| Q3 25 | $0.21 | $-0.03 | ||
| Q2 25 | $0.14 | $-0.13 | ||
| Q1 25 | $-0.77 | $-0.12 | ||
| Q4 24 | $0.07 | $-0.11 | ||
| Q3 24 | $0.12 | $-0.10 | ||
| Q2 24 | $0.08 | $-0.08 | ||
| Q1 24 | $-0.07 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $1.0B |
| 总债务越低越好 | — | $152.4M |
| 股东权益账面价值 | $534.1M | $1.7B |
| 总资产 | $946.5M | $2.3B |
| 负债/权益比越低杠杆越低 | — | 0.09× |
8季度趋势，按日历期对齐
| Q4 25 | — | $1.0B | ||
| Q3 25 | $160.2M | $976.7M | ||
| Q2 25 | $99.1M | $688.1M | ||
| Q1 25 | $51.7M | $428.4M | ||
| Q4 24 | $95.9M | $419.0M | ||
| Q3 24 | $119.3M | $442.4M | ||
| Q2 24 | $112.5M | $496.8M | ||
| Q1 24 | $132.0M | $492.5M |
| Q4 25 | — | $152.4M | ||
| Q3 25 | — | $347.0M | ||
| Q2 25 | — | $346.5M | ||
| Q1 25 | — | $345.9M | ||
| Q4 24 | — | $345.4M | ||
| Q3 24 | — | $61.2M | ||
| Q2 24 | — | $64.2M | ||
| Q1 24 | — | $66.8M |
| Q4 25 | — | $1.7B | ||
| Q3 25 | $534.1M | $1.3B | ||
| Q2 25 | $494.2M | $688.5M | ||
| Q1 25 | $530.9M | $431.3M | ||
| Q4 24 | $596.8M | $382.5M | ||
| Q3 24 | $681.4M | $419.8M | ||
| Q2 24 | $642.8M | $455.2M | ||
| Q1 24 | $618.5M | $478.9M |
| Q4 25 | — | $2.3B | ||
| Q3 25 | $946.5M | $2.2B | ||
| Q2 25 | $918.4M | $1.6B | ||
| Q1 25 | $945.9M | $1.3B | ||
| Q4 24 | $986.3M | $1.2B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.0B | $1.2B | ||
| Q1 24 | $986.6M | $1.2B |
| Q4 25 | — | 0.09× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.50× | ||
| Q1 25 | — | 0.80× | ||
| Q4 24 | — | 0.90× | ||
| Q3 24 | — | 0.15× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 0.14× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $-64.5M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $-114.2M |
| 自由现金流率自由现金流/营收 | 34.4% | -63.6% |
| 资本支出强度资本支出/营收 | 1.3% | 27.6% |
| 现金转化率经营现金流/净利润 | 1.26× | — |
| 过去12个月自由现金流最近4个季度 | $80.5M | $-321.8M |
8季度趋势，按日历期对齐
| Q4 25 | — | $-64.5M | ||
| Q3 25 | $33.8M | $-23.5M | ||
| Q2 25 | $23.4M | $-23.2M | ||
| Q1 25 | $-19.6M | $-54.2M | ||
| Q4 24 | $53.0M | $-2.4M | ||
| Q3 24 | $19.5M | $-30.9M | ||
| Q2 24 | $10.7M | $-13.0M | ||
| Q1 24 | $-16.7M | $-2.6M |
| Q4 25 | — | $-114.2M | ||
| Q3 25 | $32.6M | $-69.4M | ||
| Q2 25 | $22.0M | $-55.3M | ||
| Q1 25 | $-23.6M | $-82.9M | ||
| Q4 24 | $49.5M | $-23.9M | ||
| Q3 24 | $18.1M | $-41.9M | ||
| Q2 24 | $9.9M | $-28.3M | ||
| Q1 24 | $-17.4M | $-21.8M |
| Q4 25 | — | -63.6% | ||
| Q3 25 | 34.4% | -44.8% | ||
| Q2 25 | 23.0% | -38.3% | ||
| Q1 25 | -34.6% | -67.6% | ||
| Q4 24 | 68.8% | -18.1% | ||
| Q3 24 | 22.5% | -40.0% | ||
| Q2 24 | 13.5% | -26.7% | ||
| Q1 24 | -34.3% | -23.5% |
| Q4 25 | — | 27.6% | ||
| Q3 25 | 1.3% | 29.6% | ||
| Q2 25 | 1.5% | 22.2% | ||
| Q1 25 | 5.8% | 23.4% | ||
| Q4 24 | 4.8% | 16.3% | ||
| Q3 24 | 1.7% | 10.5% | ||
| Q2 24 | 1.1% | 14.4% | ||
| Q1 24 | 1.5% | 20.7% |
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RKLB
| Products | $94.0M | 52% |
| Transferred Over Time | $87.3M | 49% |
